Zsírmáj (MASLD/MASH): vizsgálatok itt: Dél-Korea

In Dél-Korea 15 Also abroad 366

15 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
Életkor
18 év to 80 év
People
1650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
3. fázisTaking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Bucheon-si, Busan, Deagu, Incheon, Seoul, Wŏnju
Életkor
18 év and over
People
1800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
3. fázisTaking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Bucheon-si, Busan, Incheon, Seoul, Wŏnju
Életkor
18 év and over
People
1590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Busan, Daegu, Gyeonggi-do, Incheon, Seoul
Életkor
18 év to 80 év
People
1350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Bucheon-si, Busan, Daegu, Incheon, Seoul
Életkor
18 év to 75 év
People
1800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
3. fázisTaking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Daegu, Goyang-si, Incheon, Seoul, Wŏnju
Életkor
18 év to 80 év
People
2150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
2. fázisTaking people
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Where
Busan, Daegu, Seongnam-si, Seoul
Életkor
18 év to 75 év
People
120 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05519475
3. fázisTaking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju, Junggu, Seoul, Wŏnju
Életkor
18 év and over
People
4500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
No phaseTaking people
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
Where
Daejeon
Életkor
19 év and over
People
3000
Run by
Chungnam National University Hospital
See details and how to joinNCT06519162
3. fázisTaking people
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Where
Yongin-si
Életkor
19 év to 70 év
People
226
Run by
Green Cross Wellbeing
See details and how to joinNCT06493799
4. fázisTaking people
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Where
Seongnam-si
Életkor
20 év and over
People
120
Run by
Seoul National University Bundang Hospital
See details and how to joinNCT06989723
No phaseTaking people
Establishment of NAFLD Cohort and Development of Fibrosis Markers
Where
Seoul
Életkor
18 év and over
People
1000
Run by
Seoul National University Boramae Hospital
See details and how to joinNCT02206841
No phaseNot yet taking people in Dél-Korea
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
Where
Gangwon-do, Gyeonggi-do, Seoul, Suwon, Yongin
Életkor
19 év and over
People
6000
Run by
Korea University
See details and how to joinNCT06843421
No phaseTaking people
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Where
Andong, Seoul
Életkor
19 év and over
People
10 000
Run by
Boryung Pharmaceutical Co., Ltd
See details and how to joinNCT06649162
3. fázisCsak meghívásos
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
Where
Seoul
Életkor
19 év to 74 év
People
196
Run by
Yoon Jun Kim
See details and how to joinNCT06152991